Download a PDF version.
Welcome to Scrip
Create an account to read this article
Already a subscriber?
NASH Pipeline: Racing To The Finish
As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of companies testing numerous mechanisms for the multi-factorial disease.
More from Alimentary/Metabolic
• By
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
• By
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
• By
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
• By
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
More from Therapy Areas
• By
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
• By
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
• By
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.